UNLIKE other COVID-19 vaccines that were developed using the Messenger Ribonucleic Acids (M-RNA) technology, vaccines manufactured using a killed/inactivated virus such as the Sinopharm, Sinovac and COVAXIN currently being administered in Zimbabwe do not require expensive subzero cold-chain infrastructure. By Michael Gwarisa The messenger RNA technology was deployed in the Pfizer, Mordena and other vaccines, making such vaccines unsuitable for hot climatic conditions such as the one in Zimbabwean unless the country installs a costly deep freeze airport warehouse, procures and modifies refrigerated vehicles and inoculation points to ensure the…
Read MoreSinopharm Suits Zimbabwe’s Cold Chain Capacity
